-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
The company has ranked among the Top 50 Chinese chemical pharmaceutical enterprises.
Category:
发布时间：2019-08-17
【概要描述】
On July 15, the 2019 National Pharmacy Week and China Pharmaceutical Innovation and Development Conference officially opened in Jinan, Shandong Province. During the event, the 2018 Top 100 Chinese Pharmaceutical Companies ranking series was formally announced. Leveraging its robust R&D and manufacturing capabilities as well as its steady market promotion efforts, the company was successfully included in the “2018 Top 100 Chinese Chemical Pharmaceutical Enterprises” sub-ranking of the “2018 Top 100 Chinese Pharmaceutical Companies” list, securing the 50th position. The 2018 Top 100 Chinese Pharmaceutical Companies ranking series was organized by the Minenet Research Institute, with the support of the Expert Committee for the Top 100 Chinese Pharmaceutical Companies, and is based on exclusive development and operation by Minenet in China.
On July 15, the 2019 National Pharmacy Week and China Pharmaceutical Innovation and Development Conference officially opened in Jinan, Shandong Province. During the event, the 2018 Top 100 Chinese Pharmaceutical Companies rankings were formally announced. Leveraging its robust R&D and manufacturing capabilities as well as its steady market promotion efforts, the company was successfully included in the “2018 Top 100 Chinese Chemical Pharmaceutical Enterprises” sub-ranking of the “2018 Top 100 Chinese Pharmaceutical Companies” list, securing the 50th position.
The 2018 Top 100 Chinese Pharmaceutical Companies ranking series was organized by the Expert Committee of the Top 100 Chinese Pharmaceutical Companies Ranking, under the auspices of the Minenet Research Institute. Relying on the three-terminal, six-market terminal structure database—exclusively developed and operated by Minenet for many years—the ranking evaluates pharmaceutical companies across two key dimensions: innovation-driven capability and professional promotion effectiveness. Hosted by the Southern Institute of Pharmaceutical Economics and Biaodian Information Group, the “Top 100 Chinese Pharmaceutical Companies” list is widely regarded as the “Oscars of China’s pharmaceutical industry” and is one of the most closely watched and authoritative pharmaceutical rankings in the country. The top 100 companies form the backbone of China’s pharmaceutical sector and represent the highest level of the nation’s pharmaceutical industry.
As an outstanding representative of China’s pharmaceutical industry, the company has consistently prioritized brand building, adhering to the business philosophy of “quality for the people, integrity as the foundation.” With the mission of “producing high-quality medicines for humanity,” the company has cultivated a distinguished brand culture under the “Shisi Pharmaceutical” banner through superior product quality and comprehensive, attentive service. In recent years, the company has leveraged innovation to enhance brand value, launching new projects and introducing innovative products every year, while maintaining steady and sustained growth in economic performance. On one hand, it continuously strengthens its cost competitiveness through management and technological innovation; on the other hand, by innovating its business philosophy and focusing on the supply end, it has achieved counter-cyclical growth, taking a critical step from adapting to the new normal to leading it. Over recent years, the company has steadfastly pursued a strategy of aligning innovation, quality, and branding, consistently ranking among the Top 100 Pharmaceutical Companies and emerging as a leading enterprise in the industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091